Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide

Abstract Background Despite the widespread availability of medication choices for metastatic castration-resistant prostate cancer (mCRPC), biomarkers to predict the efficacy of each mCRPC treatment have not yet been established. This study developed a prognostic nomogram and a calculator to predict...

Full description

Bibliographic Details
Main Authors: Takashi Kawahara, Yusuke Saigusa, Shuko Yoneyama, Masashi Kato, Ippei Kojima, Hiroshi Yamada, Osamu Kamihira, Kenichi Tabata, Hideyasu Tsumura, Masatsugu Iwamura, Kazuhide Makiyama, Hiroji Uemura, Yasuhide Miyoshi
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Cancer
Subjects:
CRPC
Prognosis
Enzalutamide
Abiraterone acetate
Nomogram
Online Access:https://doi.org/10.1186/s12885-023-10700-0

Internet

https://doi.org/10.1186/s12885-023-10700-0

Similar Items